↓ Skip to main content

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Overview of attention for article published in Nature, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 46,775)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Readers on

mendeley
880 Mendeley
citeulike
5 CiteULike
Title
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Published in
Nature, August 2016
DOI 10.1038/nature19323
Pubmed ID
Authors

Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H. Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling, John O’Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S. Brennan, Omar Quintero-Monzon, Robert H. Scannevin, H. Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis, Jan Grimm, Christoph Hock, Roger M. Nitsch, Alfred Sandrock, Sevigny, Jeff, Chiao, Ping, Bussière, Thierry, Weinreb, Paul H, Williams, Leslie, Maier, Marcel, Dunstan, Robert, Salloway, Stephen, Chen, Tianle, Ling, Yan, O'Gorman, John, Qian, Fang, Arastu, Mahin, Li, Mingwei, Chollate, Sowmya, Brennan, Melanie S, Quintero-Monzon, Omar, Scannevin, Robert H, Arnold, H Moore, Engber, Thomas, Rhodes, Kenneth, Ferrero, James, Hang, Yaming, Mikulskis, Alvydas, Grimm, Jan, Hock, Christoph, Nitsch, Roger M, Sandrock, Alfred

Abstract

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Twitter Demographics

The data shown below were collected from the profiles of 1,302 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 880 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 15 2%
United Kingdom 11 1%
Germany 5 <1%
Spain 5 <1%
Netherlands 4 <1%
France 3 <1%
Mexico 2 <1%
Brazil 2 <1%
Japan 2 <1%
Other 8 <1%
Unknown 823 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 229 26%
Researcher 183 21%
Student > Bachelor 130 15%
Student > Master 95 11%
Other 59 7%
Other 170 19%
Unknown 14 2%
Readers by discipline Count As %
Agricultural and Biological Sciences 266 30%
Medicine and Dentistry 170 19%
Neuroscience 118 13%
Biochemistry, Genetics and Molecular Biology 101 11%
Chemistry 65 7%
Other 146 17%
Unknown 14 2%

Attention Score in Context

This research output has an Altmetric Attention Score of 3021. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2017.
All research outputs
#73
of 7,950,197 outputs
Outputs from Nature
#28
of 46,775 outputs
Outputs of similar age
#5
of 247,460 outputs
Outputs of similar age from Nature
#2
of 982 outputs
Altmetric has tracked 7,950,197 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 46,775 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 72.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,460 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 982 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.